Accepted Manuscript



Plasma filtration for the controlled removal of liposomal therapeutics - from the apheretic site of view

M. Blaha, J. Martinkova, M. Lanska, S. Filip, J. Malakova, O. Kubecek, J. Bezouška, J. Spacek

PII: S1567-5688(17)30064-8

DOI: 10.1016/j.atherosclerosissup.2017.05.022

Reference: ATHSUP 314

To appear in: *Atherosclerosis (Supplements) (Component)*

Please cite this article as: Blaha M, Martinkova J, Lanska M, Filip S, Malakova J, Kubecek O, Bezouška J, Spacek J, Plasma filtration for the controlled removal of liposomal therapeutics - from the apheretic site of view, *Atherosclerosis (Supplements) (Component)* (2017), doi: 10.1016/j.atherosclerosissup.2017.05.022.

Plasma filtration for the controlled removal of liposomal therapeutics

- from the apheretic site of view

M. Blaha[a*], J. Martinkova[b], M. Lanska[a], S. Filip[b], J. Malakova[c], O. Kubecek[b], J. Bezouška[b], J, Spacek[d]

[a] 4th Department of Internal Medicine – Hematology, Charles University in Prague, Medical Faculty and University Hospital in Hradec Králové, Czech Republic;

[b] Department of Oncology and Radiotherapy, Charles University in Prague, Medical Faculty and University Hospital in Hradec Králové, Czech Republic;

[c] Department of Clinical Biochemistry and Diagnostics of University Hospital in Hradec Králové, Czech Republic;

[d] Department of Gynecology, Charles University in Prague, Medical Faculty and University Hospital in Hradec Králové, Czech Republic;

***Corresponding author:**

Prof. Milan Blaha. MD., Ph.D.

4th Department of Internal Medicine – Hematology, Charles University in Prague, Medical Faculty and University Hospital in Hradec Králové, Czech Republic;

Tel.: +420 495834555

e-mail: blaham@email.cz

Abstract

Introduction: Nanoparticle-based drug delivery systems can overcome the dose-limited toxicity of cytostatics. Pegylated doxorubicin-containing liposomes (PLD) are able to reduce cardiotoxicity. PLD quickly (in 2 days) attains therapeutic concentration in tumorous tissue (kinetic targeting), while its distribution in normal tissue, which is a cause of mucocutaneous toxicity (MCT), is delayed. We examined PLD extracorporeal removal effectivity, using plasma